GLP1R and diabetic kidney disease: Glucagon-like peptide-1 receptor agonists (GLP1RAs) including liraglutide and semaglutide [5], the dual GIP and GLP-1 receptor agonist tirzepatide [6], and the nonsteroidal mineralocorticoid receptor antagonist finerenone [7] have also been shown to improve cardiovascular and renal outcomes in people with DKD recently.